SVB Securities analyst Thomas Smith downgraded Axcella Health to Market Perform from Outperform with a price target of $2, down from $6, after the company discontinuing its ongoing Phase 2b trial of AXA1125 in nonalcoholic steatohepatitis.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on AXLA:
- H.C. Wainwright downgrades Axcella with discontinuation ‘major detriment’
- Axcella Health downgraded to Neutral from Buy at H.C. Wainwright
- Axcella announces corporate restructuring, will reduce workforce by 85%
- This Insider Bought Axcella Health (NASDAQ:AXLA) Stock Worth $6M
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue